Compounds that block the reactivation of latent HIV-1 in a human cell line containing the latent virus have been discovered by a team of investigators from the University of Pittsburgh. The research is published in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
The compounds the researchers tested came from a library of 418 different "kinase inhibitors." These pathways apparently include ones that can reverse latency of HIV-1 virus that has become integrated into the human genome. Thus, the research could lead to ways to permanently suppress HIV infections, said Benni E. Vargas, a Ph.D. student in Microbiology and Immunology at the University of Pittsburgh School of Medicine.
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV
Advertisement
‘Kinases target a wide range of signaling pathways within cells, regulating critical cellular functions such as DNA transcription and translation, and cellular metabolism. ’
Tweet it Now
The researchers had infected the cell line with HIV-1 that then became dormant within the cells. The virus contained a "reporter gene," which would light up during reactivation so that the investigators would know if reactivation occurred. The cell cultures were then given an HIV-1 activating small molecule compound, and each culture was exposed to one of the 418 different kinase inhibitors.
"There's a need to understand the mechanisms and signaling pathways by which the host cell regulates HIV-1 latency and reactivation," said Mr. Vargas. "What better way to identify these host signaling pathways than to screen a whole library of drugs that target different parts of the host signaling pathway?"
![Quiz on HIV Symptoms]( "Quiz on HIV Symptoms")
Do you know that there are symptoms for each stage of HIV/AIDS? Learn more from our HIV Symptom Quiz but here's a disclaimer - never go by symptoms alone. Symptoms only indicate the progression of the disease, while only a medical test can confirm it.
A potential downside of the kinase inhibitors is possible toxicity to human cells, said Mr. Vargas. The investigators gauged toxicity by measuring cellular production of ATP, a compound manufactured in cells which functions as cellular fuel, within the tiny cellular motors, the mitochondria. A notable reduction in the quantity of ATP, as present, as compared to normal, would indicate toxicity, said Mr. Vargas. Twelve kinase inhibitors blocked reactivation irrespective of latency reversing agent, and two of these did so with minimal toxicity. The motivation for the research was that several other groups had previously identified inhibitors of kinases that block reactivation of the dormant HIV-1 provirus, said Mr. Vargas.
Source: Eurekalert
Quiz on HIV Symptoms
Do you know that there are symptoms for each stage of HIV/AIDS? Learn more from our HIV Symptom Quiz but here's a disclaimer - never go by symptoms alone. Symptoms only indicate the progression of the disease, while only a medical test can confirm it.
Advertisement
A potential downside of the kinase inhibitors is possible toxicity to human cells, said Mr. Vargas. The investigators gauged toxicity by measuring cellular production of ATP, a compound manufactured in cells which functions as cellular fuel, within the tiny cellular motors, the mitochondria. A notable reduction in the quantity of ATP, as present, as compared to normal, would indicate toxicity, said Mr. Vargas. Twelve kinase inhibitors blocked reactivation irrespective of latency reversing agent, and two of these did so with minimal toxicity. The motivation for the research was that several other groups had previously identified inhibitors of kinases that block reactivation of the dormant HIV-1 provirus, said Mr. Vargas.
Source: Eurekalert
Facts on HIV / AIDS
Human Immunodeficiency Virus (HIV) usually targets the human immune system to weaken the body's defenses against infections. Here are the top facts on HIV/AIDS.
Advertisement
Advertisement
|
Advertisement
Latest AIDS/HIV News
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
